The
market for meningococcal vaccines was valued at USD 1.5 billion in
2012 and is expected to reach a value of USD 3.7 billion in 2019,
growing at a CAGR of 14.9% from 2013 to 2019.
Browse
Meningococcal Vaccines Market Report With Full TOC
http://www.transparencymarketresearch.com/meningococcal-vaccines-market.html
Meningococcal
disease is caused by the bacterium Neisseria meningitidis and occurs
sporadically throughout the world with seasonal variations. It
accounts for a proportion of endemic bacterial meningitis, which can
progress very rapidly leading to death within 24 hours from the onset
of symptoms. The disease is often misinterpreted as common flu in
most of the cases. Five out of the several serogroups are known to
cause meningococcal disease. These serogroups responsible for the
disease comprises serogroups A, B, C, Y and W-135. The causative
agent N. meningitidis is commonly found in the nasopharynx of humans
and gets transmitted through droplet inhalation by means of close
contact such as exposure to smokers, crowded living conditions such
as dormitories, certain inherited disorders of the immune system,
functional/anatomical asplenia or though intimate oral contact among
others. According to European Federation of Pharmaceutical Industries
and Association every year meningitis affects almost 5 lakh people
globally, primarily affecting toddlers, infants and young adults, due
to weaker immune system.
The
global market for meningococcal vaccines is segmented broadly into
vaccine types namely, polysaccharide, conjugate and combination
vaccines. The report also provides analysis for vaccines under
development that are expected to be commercialized during the
forecast period 2013 to 2019. The vaccine types are further segmented
by different brands available in the market. The conjugate vaccines
segment is likely to lead the overall meningococcal vaccines market
in terms of revenue, which is estimated to reach approximately USD
2.5 billion by 2019 at a CAGR of 12.9%. Amongst the pipeline
vaccines, Novartis's Bexsero is expected to grow at the fastest rate
of 24.7% during the forecast period 2013 to 2019. According to
Department of Health, U.K., Bexsero is the first serogroup B vaccine
to be incorporated into the national immunization program and is
expected to be available in the market for sales by the second
quarter of 2014. The MnB rLP2086 vaccine from Pfizer is currently in
phase III clinical trials and has been granted with Breakthrough
Therapy status by U.S. FDA in 2014.
Request
for customization of this report
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1666
Geographically,
North America lead the global meningococcal vaccines market in 2012
due to government interventions, wider immunization programs, and
favorable research and development initiative by manufacturers.
According to National Meningitis Association of the U.S., about 20
percent of all meningococcal disease cases occur in teens and young
adults aged 14 years to 24 years. As per the Centers for Disease
Control and Prevention (CDC) 1,000 to 2,600 people contract
meningitis annually in the U.S. Meningococcal vaccines licensed in
the U.S. are only against A, C, Y and W-135 serogroups and not
against serogroup B. The use of Bexsero as an Investigational New
Drug (IND) in combating the disease during the outbreaks in Princeton
University and University of California, Santa Barbara in 2013, is
likely to clear the way for Bexsero's approval in the U.S. market
sooner than expected. This region is followed by Rest of the World
comprising the Latin American countries, the Middle East and African
countries. This has been attributed to the high incidence rate of
meningococcal diseases in this region. Europe accounts for the lowest
CAGR due to rise free sales of the vaccines especially meningococcal
C vaccines.
Browse
All Market Research Reports:
http://www.transparencymarketresearch.com/categories.html
By
2019, Asia-Pacific is estimated to be the fastest growing regional
market with a CAGR of around 17.1%. Major drivers for this market
include low cost of manufacturing and transfer of novel technologies
with respect to vaccine manufacturing, from developed parts of the
world to the emerging economies. Advancements in manufacturing
technology have been helping companies in manufacturing novel
products that are not only affordable in developing and
underprivileged nations, but are also comparable in terms of quality
to their high-end alternatives.
Browse
Market Research Articles:
http://www.transparencymarketresearch.com/articles.htm
The
global market for meningococcal vaccines is largely driven by
increasing government intervention in reforming the healthcare
infrastructure and incorporation of legislations specific to
meningococcal vaccination. The public-private partnerships for
conducting research and development, and manufacturing of quality
vaccines at an affordable price are also contributing positively in
driving market growth. Awareness campaigning from government and
non-profit organizations and obligatory immunization for individuals
heading to Mecca (for Hajj pilgrimage) and the South African
meningitis belt will also contribute to growth of this market. High
cost of few but vital vaccines, such as Bexsero, and need for
efficient cold chain logistics to maintain safety and efficacy of the
vaccine are expected to be some of the major factors posing a
challenge to the adequate uptake of these vaccines.
Browse
all Press Releases:
http://www.transparencymarketresearch.com/press-releases.htm
The
key players dominating in the global meningococcal vaccines include
Sanofi Pasteur (the vaccine division of Sanofi SA), Novartis
International AG and GSK plc. These players account for more than 80%
of the meningococcal vaccines market. Players such as Serum Institute
of India Ltd., JN International Medical Corporation, Biomed Pvt.
Ltd., Nuron Biotech and Baxter account for the remaining market
share.
Browse
all Article :
http://www.transparencymarketresearch.com/articles.htm
The
global meningococcal vaccines market is segmented as follow:
Meningococcal
Vaccines Market, by Type
Polysaccharide
Vaccines, by Brand
Menomune
Mencevax
NmVac4
Others
Quadri
Meningo
Bi
Meningo
Conjugate
Vaccines, by Brand
Menactra
Menveo
NeisVac-C
Nimenrix
Meningitec
Menjugate
MenAfriVac
Combination
Vaccines, by Brand
MenHibrix
Menitorix
Pipeline
Vaccines, by Brand
Bexsero
MnB
rLP2806
NmVac4-DT
Meningococcal
Vaccines Market, by Geography
North
America
Europe
Asia-Pacific
Rest
of the World
Browse
Pharmaceutical Market Reports @
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
About
Us
Transparency
Market Research is a global market intelligence company, providing
global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. Our
experienced team of Analysts, Researchers, and Consultants, use
proprietary data sources and various tools and techniques to gather,
and analyze information.
Our
data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability,
Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research
material for business reports.
Contact
Ms.
Sheela AK
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA
- Canada Toll Free: 866-552-3453
No comments:
Post a Comment